Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $0.74 in the prior trading day, TransCode Therapeutics Inc (NASDAQ: RNAZ) closed at $0.78, up 4.82%. In other words, the price has increased by $4.82 from its previous closing price. On the day, 12.71 million shares were traded. RNAZ stock price reached its highest trading level at $0.84 during the session, while it also had its lowest trading level at $0.645.
Ratios:
Our goal is to gain a better understanding of RNAZ by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.58 and its Current Ratio is at 1.58. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNAZ now has a Market Capitalization of 541543 and an Enterprise Value of -1316435.
Stock Price History:
The Beta on a monthly basis for RNAZ is 1.49, which has changed by -0.9651246 over the last 52 weeks, in comparison to a change of 0.09506309 over the same period for the S&P500. Over the past 52 weeks, RNAZ has reached a high of $66.33, while it has fallen to a 52-week low of $0.74. The 50-Day Moving Average of the stock is -85.61%, while the 200-Day Moving Average is calculated to be -94.79%.
Shares Statistics:
The stock has traded on average 2.26M shares per day over the past 3-months and 4134880 shares per day over the last 10 days, according to various share statistics. A total of 0.70M shares are outstanding, with a floating share count of 0.66M. Insiders hold about 5.08% of the company’s shares, while institutions hold 26.18% stake in the company. Shares short for RNAZ as of 1740700800 were 540931 with a Short Ratio of 0.24, compared to 1738281600 on 368311. Therefore, it implies a Short% of Shares Outstanding of 540931 and a Short% of Float of 77.699995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of TransCode Therapeutics Inc (RNAZ) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$1.48, with high estimates of -$1.48 and low estimates of -$1.48.
Analysts are recommending an EPS of between -$4.76 and -$4.76 for the fiscal current year, implying an average EPS of -$4.76. EPS for the following year is -$4.37, with 1.0 analysts recommending between -$4.37 and -$4.37.
